Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ipilimumab

View Patient Information
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
ipilimumab biosimilar CS1002
MOAB CTLA-4
monoclonal antibody CTLA-4
US brand name:Yervoy
Abbreviation:MDX-CTLA-4
Code name:BMS-734016
IBI310
MDX-010
IND number:10200
NSC code:720801
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search